论文部分内容阅读
近30年来由于新的化疗药物不断出现和治疗方法的改进,急性淋巴细胞型白血病(ALL)的缓解率和生存时间都有了明显的提高。但是有些病例用一般剂量治疗很难取得缓解或复发后很难取得再次缓解,被称为难治性急性淋巴细胞型白血病。用大剂量化疗尤其是大剂量氨甲喋呤方案(HDMT
In the past 30 years, due to the continuous appearance of new chemotherapy drugs and the improvement of treatment methods, the acute lymphoblastic leukemia (ALL) remission rate and survival time have been significantly improved. However, in some cases it is difficult to achieve remission again after the treatment with the general dose is difficult to achieve remission, which is called refractory acute lymphoblastic leukemia. With high-dose chemotherapy, especially high-dose methotrexate program (HDMT